Department of Urology, University of Rochester Medical Center, Rochester, New York, USA; Quantitative Safety and Epidemiology, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
Department of Urology, University of Rochester Medical Center, Rochester, New York, USA.
Eur Urol Focus. 2017 Dec;3(6):599-605. doi: 10.1016/j.euf.2017.02.015. Epub 2017 Apr 4.
In the European Organization for Research and Treatment of Cancer (EORTC) randomized trial 30904, nephron-sparing surgery (NSS) reduced the risk of renal dysfunction compared with radical nephrectomy (RN); however, overall survival was better in the RN arm.
To determine whether treatment effect on the risk of renal dysfunction and all-cause mortality differed in magnitude across levels of baseline variables.
DESIGN, SETTING, AND PARTICIPANTS: This was an exploratory subgroup analysis of EORTC 30904, a phase 3 randomized trial conducted in patients with a small (≤5cm) renal mass and normal contralateral kidney.
Patients were randomized to RN (n=273) or NSS (n=268).
End points included follow-up estimated glomerular filtration rate (eGFR) <60ml/min/1.73m, eGFR <45ml/min/1.73m, eGFR <30ml/min/1.73m, and all-cause mortality. Treatment effect was examined within baseline variables: age (<62 vs ≥62 yr), sex, chronic disease (any vs none), performance status (0 vs≥1), and serum creatinine ≤1.25 vs >1.25×upper limit of normal (ULN). Logistic and Cox regression models were used for analysis of renal dysfunction and all-cause mortality, respectively.
The median follow-up periods were 6.7 yr for eGFR and 9.3 yr for survival. No variable-by-treatment interactions were significant at alpha=0.05. For patients with baseline creatinine >1.25×ULN (n=36), estimated mortality hazard ratio (HR) for NSS versus RN reversed its direction (HR=0.76, 95% confidence interval [CI]: 0.17-3.39) relative to the rest of the study cohort (HR=1.56, 95% CI: 1.06-2.29), although this reversal was not statistically significant (interaction p=0.25). This analysis was limited by low power.
This exploratory analysis did not reveal strong evidence of treatment effect modification in EORTC 30904, but it was limited by low power.
We aimed to determine whether the effect of partial versus radical nephrectomy on kidney function and overall survival depended on age, sex, and baseline health of patients enrolled in a large clinical trial. Such dependence could not be demonstrated in this analysis.
在欧洲癌症研究与治疗组织(EORTC)的随机试验 30904 中,与根治性肾切除术(RN)相比,保留肾单位手术(NSS)降低了肾功能障碍的风险;然而,RN 组的总生存情况更好。
确定治疗对肾功能障碍和全因死亡率风险的影响是否在基线变量水平上存在显著差异。
设计、地点和参与者:这是 EORTC 30904 的一项探索性亚组分析,该试验是一项在患有小(≤5cm)肾肿瘤且对侧肾脏正常的患者中进行的 3 期随机试验。
患者被随机分配到 RN 组(n=273)或 NSS 组(n=268)。
终点包括随访时估计肾小球滤过率(eGFR)<60ml/min/1.73m、eGFR<45ml/min/1.73m、eGFR<30ml/min/1.73m 和全因死亡率。在基线变量内检查治疗效果:年龄(<62 岁与≥62 岁)、性别、慢性疾病(有或无)、表现状态(0 与≥1)和血清肌酐≤1.25 倍与正常上限(ULN)相比>1.25 倍。分别使用逻辑回归和 Cox 回归模型分析肾功能障碍和全因死亡率。
eGFR 的中位随访期为 6.7 年,生存的中位随访期为 9.3 年。在 alpha=0.05 时,没有变量与治疗的交互作用具有统计学意义。对于基线肌酐>1.25×ULN(n=36)的患者,与研究队列的其余部分相比,NSS 与 RN 的估计死亡率风险比(HR)发生了逆转(HR=0.76,95%置信区间[CI]:0.17-3.39),尽管这种逆转没有统计学意义(交互作用 p=0.25)。这项分析受到低效能的限制。
这项探索性分析并未显示 EORTC 30904 中治疗效果存在明显的修饰作用,但受到低效能的限制。
我们旨在确定部分肾切除术与根治性肾切除术对参加大型临床试验的患者的肾功能和总体生存的影响是否取决于年龄、性别和基线健康状况。在这项分析中,无法证明存在这种依赖性。